Skip to main content

Welcome to Janssen Canada

VISIT JANSSEN GLOBAL

Title

Media

15, October, 2021

Toronto

OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)

13, September, 2021

Toronto

^NSPRAVATO® (esketamine)* Nasal Spray Authorized in Canada, for Short-Term Treatment, for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Requiring Urgent Psychiatric Care

11, June, 2021

Toronto

Johnson & Johnson Statement on Supply of COVID-19 Vaccine Currently on Hold in Canada

19, April, 2021

Toronto

DARZALEX® SC Becomes the First and Only Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis, A Rare Disease

04, March, 2021

Toronto

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use

13, January, 2021

Toronto

Health Canada Approves IMBRUVICA^® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

22, December, 2020

Toronto

Janssen Announces Health Canada Approval of DARZALEX®* Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

01, December, 2020

Toronto

Johnson & Johnson Announces the Initiation of a Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with Health Canada

10, September, 2020

Toronto

Health Canada Approves TREMFYA®* (guselkumab injection), a First-In-Class Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

31, August, 2020

Toronto

Johnson & Johnson Announces Agreement in Principle with Government of Canada to Supply its COVID-19 Vaccine Candidate